Bank of New York Mellon’s Cyclerion Therapeutics CYCN Stock Holding History

Bank of New York Mellon’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,326	Closed	-$74K	–	4609
2022 Q1	$74K	Sell	3,326 -14	-0.4%	-$337	﹤0.01%	4461
2021 Q4	$114K	Hold	3,340	–	–	﹤0.01%	4386
2021 Q3	$205K	Hold	3,340	–	–	﹤0.01%	4207
2021 Q2	$260K	Sell	3,340 -1,561	-32%	-$97.7K	﹤0.01%	4009
2021 Q1	$273K	Sell	4,901 -102	-2%	-$7.66K	﹤0.01%	3948
2020 Q4	$306K	Buy	5,003 +583	+13%	+$39.7K	﹤0.01%	3824
2020 Q3	$538K	Sell	4,420 -28	-0.6%	-$3.2K	﹤0.01%	3456
2020 Q2	$526K	Sell	4,448 -360	-7%	-$30.1K	﹤0.01%	3443
2020 Q1	$255K	Sell	4,808 -9	-0.2%	-$642	﹤0.01%	3667
2019 Q4	$262K	Buy	4,817 +537	+13%	+$50.1K	﹤0.01%	3841
2019 Q3	$1.04M	Buy	4,280 +395	+10%	+$85.3K	﹤0.01%	3164
2019 Q2	$890K	Buy	+3,885	New	+$1.1M	﹤0.01%	3296

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TFS

TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.7% 1-Year Est. Return

Bank of New York Mellon's CYCN Position: Q2 2022 in Review

Bank of New York Mellon sold out of Cyclerion Therapeutics (CYCN) in Q2 2022, closing a stake of 3,326 shares — an estimated $74K sold.

Bank of New York Mellon first reported a position in CYCN in Q2 2019 and held it in 12 quarters. The position peaked at $1.04M in Q3 2019. 41 funds tracked by Wall St. Rank hold CYCN as of Q2 2022.

Bank of New York Mellon reported no remaining Cyclerion Therapeutics position as of Q2 2022 after selling out during the quarter.
Bank of New York Mellon sold 3,326 Cyclerion Therapeutics shares in Q2 2022, an estimated $74K.
Bank of New York Mellon first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 12 quarters.
Bank of New York Mellon's Cyclerion Therapeutics position peaked at $1.04M in Q3 2019.
41 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.